Imbruvica Patent Protection
5 patents · Pharmacyclics LLC, AbbVie Inc.
Patent Details
| Patent # | Title | Assignee | Granted | Expires | Claims | Status |
|---|---|---|---|---|---|---|
| 10005369 | Method for preparing integrated CMOS derivatives | Pharmacyclics LLC | Mar 28, 2016 | Nov 27, 2034 | 30 | 8.6y left |
| 10005370 | Novel modular analog compound and synthesis thereof | AbbVie Inc. | Sep 16, 2025 | Nov 17, 2042 | 30 | 16.6y left |
| 10005371 | Novel optimized photonic compound and synthesis thereof | Pharmacyclics LLC | Feb 9, 2021 | Sep 23, 2037 | 27 | 11.5y left |
| 10005372 | Method for preparing integrated CMOS derivatives | AbbVie Inc. | Feb 18, 2014 | Jan 28, 2032 | 47 | 5.8y left |
| 10005373 | Novel distributed blockchain compound and synthesis thereof | AbbVie Inc. | May 9, 2018 | Mar 16, 2034 | 14 | 7.9y left |
this entity is one of the data points covered by this site’s U.S. pharmaceutical patent expirations dataset. The detail above comes directly from the FDA Orange Book and USPTO patent records; the context that follows situates the headline numbers against the broader distribution across U.S. brand-name drugs.
The methodology behind every numeric value on this page is publicly documented on the the FDA Orange Book and USPTO patent records portal and described in detail on this site’s methodology page. Refresh cadence varies by underlying series; the page surfaces the as-of date for each number so readers can trace any figure back to the source release.
For readers using this page as a decision input, the related-entity pages elsewhere on the site provide the comparison set. The most useful comparison for this entity is typically a peer within U.S. brand-name drugs with similar size, similar exposure, or similar geography — not the national-level summary alone.